214 related articles for article (PubMed ID: 21511863)
21. Dynamic susceptibility contrast (DSC) perfusion MRI in differential diagnosis between radionecrosis and neoangiogenesis in cerebral metastases using rCBV, rCBF and K2.
Muto M; Frauenfelder G; Senese R; Zeccolini F; Schena E; Giurazza F; Jäger HR
Radiol Med; 2018 Jul; 123(7):545-552. PubMed ID: 29508242
[TBL] [Abstract][Full Text] [Related]
22. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
Barajas RF; Chang JS; Segal MR; Parsa AT; McDermott MW; Berger MS; Cha S
Radiology; 2009 Nov; 253(2):486-96. PubMed ID: 19789240
[TBL] [Abstract][Full Text] [Related]
23. Association of dynamic susceptibility contrast enhanced MR Perfusion parameters with prognosis in elderly patients with glioblastomas.
Jabehdar Maralani P; Melhem ER; Wang S; Herskovits EH; Voluck MR; Kim SJ; Learned KO; O'Rourke DM; Mohan S
Eur Radiol; 2015 Sep; 25(9):2738-44. PubMed ID: 25680731
[TBL] [Abstract][Full Text] [Related]
24. Perfusion magnetic resonance imaging characteristics of intracerebral tuberculomas and its role in differentiating tuberculomas from metastases.
Sankhe S; Baheti A; Ihare A; Mathur S; Dabhade P; Sarode A
Acta Radiol; 2013 Apr; 54(3):307-12. PubMed ID: 23319719
[TBL] [Abstract][Full Text] [Related]
25. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].
Lev MH; Ozsunar Y; Henson JW; Rasheed AA; Barest GD; Harsh GR; Fitzek MM; Chiocca EA; Rabinov JD; Csavoy AN; Rosen BR; Hochberg FH; Schaefer PW; Gonzalez RG
AJNR Am J Neuroradiol; 2004 Feb; 25(2):214-21. PubMed ID: 14970020
[TBL] [Abstract][Full Text] [Related]
26. Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
Barajas RF; Chang JS; Sneed PK; Segal MR; McDermott MW; Cha S
AJNR Am J Neuroradiol; 2009 Feb; 30(2):367-72. PubMed ID: 19022867
[TBL] [Abstract][Full Text] [Related]
27. Multiparametric magnetic resonance imaging to differentiate high-grade gliomas and brain metastases.
Mouthuy N; Cosnard G; Abarca-Quinones J; Michoux N
J Neuroradiol; 2012 Dec; 39(5):301-7. PubMed ID: 22197404
[TBL] [Abstract][Full Text] [Related]
28. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements.
Hu LS; Baxter LC; Smith KA; Feuerstein BG; Karis JP; Eschbacher JM; Coons SW; Nakaji P; Yeh RF; Debbins J; Heiserman JE
AJNR Am J Neuroradiol; 2009 Mar; 30(3):552-8. PubMed ID: 19056837
[TBL] [Abstract][Full Text] [Related]
29. Combined value of susceptibility-weighted and perfusion-weighted imaging in assessing who grade for brain astrocytomas.
Wang XC; Zhang H; Tan Y; Qin JB; Wu XF; Wang L; Zhang L
J Magn Reson Imaging; 2014 Jun; 39(6):1569-74. PubMed ID: 24987755
[TBL] [Abstract][Full Text] [Related]
30. Multiparametric analysis from dynamic susceptibility contrast-enhanced perfusion MRI to evaluate malignant brain tumors.
Abreu VS; Tarrio J; Silva J; Almeida F; Pinto C; Freitas D; Filipe JP
J Neuroimaging; 2024; 34(2):257-266. PubMed ID: 38173078
[TBL] [Abstract][Full Text] [Related]
31. High- and low-grade glioma differentiation: the role of percentage signal recovery evaluation in MR dynamic susceptibility contrast imaging.
Aprile I; Giovannelli G; Fiaschini P; Muti M; Kouleridou A; Caputo N
Radiol Med; 2015 Oct; 120(10):967-74. PubMed ID: 25762408
[TBL] [Abstract][Full Text] [Related]
32. Comparison of three different MR perfusion techniques and MR spectroscopy for multiparametric assessment in distinguishing recurrent high-grade gliomas from stable disease.
Seeger A; Braun C; Skardelly M; Paulsen F; Schittenhelm J; Ernemann U; Bisdas S
Acad Radiol; 2013 Dec; 20(12):1557-65. PubMed ID: 24200483
[TBL] [Abstract][Full Text] [Related]
33. Comparison of first-pass and second-bolus dynamic susceptibility perfusion MRI in brain tumors.
Spampinato MV; Wooten C; Dorlon M; Besenski N; Rumboldt Z
Neuroradiology; 2006 Dec; 48(12):867-74. PubMed ID: 17013587
[TBL] [Abstract][Full Text] [Related]
34. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
[TBL] [Abstract][Full Text] [Related]
35. Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.
Law M; Young R; Babb J; Rad M; Sasaki T; Zagzag D; Johnson G
AJNR Am J Neuroradiol; 2006 Oct; 27(9):1975-82. PubMed ID: 17032878
[TBL] [Abstract][Full Text] [Related]
36. Absolute CBV for the differentiation of recurrence and radionecrosis of brain metastases after gamma knife radiotherapy: a comparison with relative CBV.
Wang B; Zhao B; Zhang Y; Ge M; Zhao P; Na Sun ; Li C; Pang Q; Xu S; Liu Y
Clin Radiol; 2018 Aug; 73(8):758.e1-758.e7. PubMed ID: 29764622
[TBL] [Abstract][Full Text] [Related]
37. Differentiating enhancing multiple sclerosis lesions, glioblastoma, and lymphoma with dynamic texture parameters analysis (DTPA): A feasibility study.
Verma RK; Wiest R; Locher C; Heldner MR; Schucht P; Raabe A; Gralla J; Kamm CP; Slotboom J; Kellner-Weldon F
Med Phys; 2017 Aug; 44(8):4000-4008. PubMed ID: 28543071
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging of solitary brain metastases: main findings of nonmorphological sequences.
Gaudino S; Di Lella GM; Russo R; Lo Russo VS; Piludu F; Quaglio FR; Gualano MR; De Waure C; Colosimo C
Radiol Med; 2012 Oct; 117(7):1225-41. PubMed ID: 22744350
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases.
Fan B; Li M; Wang X; Xu Y; Li F; Zhang L; Jiang J; Jiang Y
J Magn Reson Imaging; 2017 Jun; 45(6):1827-1834. PubMed ID: 27696616
[TBL] [Abstract][Full Text] [Related]
40. Differentiation between primary central nervous system lymphoma and glioblastoma: a comparative study of parameters derived from dynamic susceptibility contrast-enhanced perfusion-weighted MRI.
Nakajima S; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Arakawa Y; Takagi Y; Miyamoto S; Togashi K
Clin Radiol; 2015 Dec; 70(12):1393-9. PubMed ID: 26382744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
